Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 Inhibitors

inhibited tumor growth in the BRCA mutant MDA-MB-436 xenograft model and showed synergistic efficacy in combination with irinotecan in the HCT116 xenograft model, suggesting that it could be a promising candidate drug combined with chemotherapy for the treatment of cancer. These findings indicate that the strategy proposed in this study is highly significant for the development of selective PARP1 inhibitors.